Athanor Capital’s Prelude Therapeutics PRLD Stock Holding History

Athanor Capital’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-3,374	Closed	-$241K	–	997
2020 Q4	$241K	Buy	+3,374	New	+$168K	0.01%	617

Other funds holding PRLD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Athanor Capital's PRLD Position: Q1 2021 in Review

Athanor Capital sold out of Prelude Therapeutics (PRLD) in Q1 2021, closing a stake of 3,374 shares — an estimated $241K sold.

Athanor Capital first reported a position in PRLD in Q4 2020 and held it in 1 quarter. The position peaked at $241K in Q4 2020. 60 funds tracked by Wall St. Rank hold PRLD as of Q1 2021.

Athanor Capital reported no remaining Prelude Therapeutics position as of Q1 2021 after selling out during the quarter.
Athanor Capital sold 3,374 Prelude Therapeutics shares in Q1 2021, an estimated $241K.
Athanor Capital first reported a position in Prelude Therapeutics in Q4 2020 and held it in 1 quarter.
Athanor Capital's Prelude Therapeutics position peaked at $241K in Q4 2020.
60 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.